Brintellix

Brintellix®

(vortioxetine)

19 Aug, 2023

Mind Matters with Dr Greg Mattingly

Dr Gregory Mattingly discusses in this series of interview vignettes his clinical and academic experience with Brintellix^® (vortioxetine) in the treatment of adults with major depressive disorder.¹

These vignettes demonstrate Dr Mattingly’s evidence-based management approach to the application of Brintellix^® data to real-world case studies.

31 Oct, 2023

Think Depression. Think Brintellix®

28 Jul, 2023

Clinical experience in treating MDD patients with Brintellix® (vortioxetine) (1)

01 Aug, 2023

Treating the broad spectrum of depressive symptoms

01 Aug, 2023

Treating MDD patients with an inadequate response to prior treatment with an SSRI/SNRI

Body

Brintellix PBS information: This product is not listed on the PBS.
Body

Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

Brintellix PI

Brintellix is a registered trademark of H. Lundbeck A/S.

Contributor

Dr Gregory W. Mattingly

MD, Associate Professor Washington University School of Medicine President, Midwest Group, St. Louis, Missouri, USA

Brintellix

Brintellix®

Mind Matters with Dr Greg Mattingly

Think Depression. Think Brintellix®

Clinical experience in treating MDD patients with Brintellix® (vortioxetine) (1)

Treating the broad spectrum of depressive symptoms

Treating MDD patients with an inadequate response to prior treatment with an SSRI/SNRI

References

Contributor

BROUGHT TO YOU BY

LUNDBECK AUSTRALIA PRODUCTS

subscribe newsletter